178979-85-6

Usage

Uses

Antiviral (reverse transcriptase inhibitor).

InChI:InChI=1/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)

Upstream product

• 1189-71-5 isocyanate de chlorosulfonyle 
• 178981-89-0 2-Hydroxymethyl-5-(3,5-dichlorophenylthio)-4-isopropyl-1-(pyridin-4-yl)methyl-1H-imidazole 
• 209743-76-0 2-carbamoyloxymethyl-4-isopropyl-1-(pyridin-4-yl)methyl-1H-imidazole 
• 74282-78-3 3,5-dichlorobenzenesulfenyl chloride 

Relevant academic research and scientific papers

Process for producing arylsulfenyl halide

A process for producing a compound of the formula (II): wherein Hal1 represents halogen and R1 and R2 each independently represents halogen, alkyl, alkoxy, nitro or cyano, which comprises allowing a halogenating agent to react with a compound of the formula (I): wherein Alk represents branched alkyl and R1 and R2 are as defined above.

Method for carbamoylating alcohols

The present invention includes a method for carbamoylating an alcohol with sodium cyanate in the presence of methanesulfonic acid. The reaction can be conducted under anhydrous conditions. This method is suitable for carbamoylating a molecule including both an alcohol moiety and a basic moiety and/or a molecule including both an alcohol moiety and a sulfenyl moiety, such as the sulfenyl alcohol precursor of the antiviral agent Capravirine.

Process for the preparation of carbamoylated imidazole derivatives

PCT No. PCT/JP97/04706 Sec. 371 Date Jun. 10, 1999 Sec. 102(e) Date Jun. 10, 1999 PCT Filed Dec. 19, 1997 PCT Pub. No. WO98/29394 PCT Pub. Date Jul. 9, 1998The present invention provides a process for the preparation of a compound of the formula (III): wherein R1 is an optionally substituted alkyl or an optionally substituted aryl; R2 is an optionally substituted alkyl: R3 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aralkyl, or an optionally substituted heteroarylalkyl; and n is an integer of 1-3, which comprises reacting a compound of the formula (I): wherein R1, R2, and n are as defined above, with a compound of the formula (II):R3OH(II)wherein R3 is as defined above, in the presence of phosphine and either of dialkyl azodicarboxylate and tetraalkyl azodicarboxamide.

Lymph-absorbable aryl substituted imidazole derivatives

PCT No. PCT/JP97/00813 Sec. 371 Date Jul. 21, 1998 Sec. 102(e) Date Jul. 21, 1998 PCT Filed Mar. 14, 1997 PCT Pub. No. WO97/35843 PCT Pub. Date Oct. 2, 1997A compound of the formula (I): salt thereof, or hydrate thereof which can effectively be absorbed from the lymph vessel in the intestinal tract and transferred to the lymph node in a high concentration is provided.

Process for producing imidazole derivatives

PCT No. PCT/JP97/04708 Sec. 371 Date Jun. 10, 1999 Sec. 102(e) Date Jun. 10, 1999 PCT Filed Dec. 19, 1997 PCT Pub. No. WO98/29395 PCT Pub. Date Jul. 9, 1998The present invention provides a process for producing a compound of the formula (III): wherein R1 and R3 are independently hydrogen or an organic group; R2 is an organic group; and R4 is an optionally substituted aryl. by reacting the compound of formula (I): wherein R1, R2, and R3 are as defined above, with the compound of formula (II):R4-S-Hal(II)wherein R4 is as defined above and Hal is halogen, in the presence of base.

Imidazole derivatives as anti-HIV agents

An imidazole derivative represented by general formula (I) or a salt thereof, having the effect of specifically inhibiting the growth of HIV as a pathogenic virus and being reduced in toxicity. In said formula R1 represents hydrogen, C1 -C20 alkyl, C2 -C7 alkenyl, C4 -C12 cycloalkylalkyl, etc.; R2 represents C1 -C6 alkyl, C1 -C6 acyl, hydroxyiminomethyl, hydrazonomethyl or --(CH2)n--R4 (R4 being halogeno, alkoxy, hydroxy, etc.; and n being an integer of 1 to 3); R3 represents substituted or unsubstituted C1 -C6 alkyl; X and Y represent each independently hydrogen, C1 -C3 alkyl, halogeno, or nitro; and Z represents S, SO, SO2 or CH2. STR1